Awakn Life Sciences Corp (NEO:AWKN) CEO Anthony Tennyson tells Proactive he's excited the psychedelics-focused biotechnology group has listed on the NEO Exchange in Canada, as the support of the capital markets will help Awakn treat more people suffering with alcohol use disorder.
Tennyson explains how the group has been progressing with its MDMA and Ketamine-focused therapeutics to treat the disease as well as establishing its UK-based clinics to administer these drugs to help treat patients. The aim is to have 3 clinics open in the UK by the end of 2021.